Theravance Q1 2024 Earnings Report

Theravance reported a solid first quarter in 2024, driven by YUPELRI hospital sales and progress in CYPRESS execution.

Key Takeaways

Theravance Biopharma reported its first quarter 2024 financial results, highlighting a solid performance in YUPELRI hospital sales and ongoing progress with the CYPRESS study for ampreloxetine.

YUPELRI delivered a solid quarter of hospital sales execution.

The company is focused on YUPELRI growth and CYPRESS execution.

A virtual investor event is scheduled for May 23rd to discuss ampreloxetine progress.

The next milestone payment of $25.0 million will be triggered if Royalty Pharma receives $240.0 million or more in royalty payments from GSK with respect to 2024 TRELEGY global net sales.

Total Revenue

$14.5M

Previous year: $10.4M

+39.2%

EPS

-$0.09

Previous year: -$0.24

-62.5%

YUPELRI U.S. Net Sales

$55.2M

TRELEGY Global Net Sales

$749M